Lyrica Approved for Neuropathic Pain Associated with Spinal Cord Injury
Just when you didn’t think it was possible, MSAs got more expensive again. Brace yourself for the wave of higher counters because Pfizer has just announced FDA approval of Lyrica for neuropathic pain associated with spinal cord injury. A phase 3 study conducted by Pfizer involving 357 patients in 10 countries showed that Lyrica significantly reduced neuropathic pain associated with spinal cord injury from baseline throughout the duration of the 12 to 16 week studies. Patients receiving Lyrica showed a 30% and 50% reduction in pain. Good news from an MSA perspective is that we can stop guessing about the inconsistent application of the off-label drug rule by CMS on this one from now on. Sorry that didn’t make anyone feel any better.
Click here for more information about the FDA approval.